Literature DB >> 22469418

Effects of natural S-equol supplements on overweight or obesity and metabolic syndrome in the Japanese, based on sex and equol status.

Takeshi Usui1, Mayu Tochiya, Yousuke Sasaki, Kazuya Muranaka, Hajime Yamakage, Akihiro Himeno, Akira Shimatsu, Asami Inaguma, Tomomi Ueno, Shigeto Uchiyama, Noriko Satoh-Asahara.   

Abstract

OBJECTIVES: Epidemiologic studies indicate that soy intake has an important role in the prevention of age-related health problems. Daidzein, the principal isoflavone contained in soy, is converted to S-equol by the intestinal bacteria. Not all individuals, however, can produce S-equol, which is considered the most biologically active metabolite. We studied the effects of a natural S-equol supplement on metabolic parameters associated with overweight or obesity and metabolic syndrome.
METHODS: The study was a randomized, double-blinded, placebo-controlled, crossover design with no washout period. All subjects were considered overweight or obese if they had a body mass index ≥ 25 kg/m(2) . Placebo or natural S-equol tablets containing 10 mg S-equol were orally ingested each day for 12 weeks. A total of 54 Japanese overweight or obese outpatients were enrolled. The equol phenotype was determined, and various metabolic parameters, including cardio-ankle vascular index (CAVI), were measured.
RESULTS: Equol non-producers comprised 67.9% of the overweight or obese subjects. The ratio of equol non-producers in this overweight or obese subject group was higher than the previously reported ratio of equol non-producers (approximately 50%) in the general population. Compared with the placebo group, intervention with natural S-equol led to a significant decrease in HbA1c, serum low-density lipoprotein cholesterol (LDL-C) levels and CAVI score. Furthermore, the effect was more prominent in the subgroup of female equol non-producers.
CONCLUSION: The ratio of equol non-producers in overweight or obese populations might be higher than generally reported. Natural S-equol might have a role in glycaemic control and in the prevention of cardiovascular disease by its effects to lower LDL-C levels and CAVI scores in overweight or obese individuals.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22469418     DOI: 10.1111/j.1365-2265.2012.04400.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  43 in total

1.  Opposing effects of S-equol supplementation on metabolic and behavioral parameters in mice fed a high-fat diet.

Authors:  Erin N Bax; Karlee E Cochran; Jiude Mao; Charles E Wiedmeyer; Cheryl S Rosenfeld
Journal:  Nutr Res       Date:  2018-12-21       Impact factor: 3.315

2.  A Mitochondrial Biomarker-Based Study of S-Equol in Alzheimer's Disease Subjects: Results of a Single-Arm, Pilot Trial.

Authors:  Heather M Wilkins; Jonathan D Mahnken; Paul Welch; Rebecca Bothwell; Scott Koppel; Richard L Jackson; Jeffrey M Burns; Russell H Swerdlow
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 3.  Role of phytoestrogens in prevention and management of type 2 diabetes.

Authors:  Mohammad Talaei; An Pan
Journal:  World J Diabetes       Date:  2015-03-15

Review 4.  Put "gender glasses" on the effects of phenolic compounds on cardiovascular function and diseases.

Authors:  Ilaria Campesi; Maria Marino; Manuela Cipolletti; Annalisa Romani; Flavia Franconi
Journal:  Eur J Nutr       Date:  2018-04-25       Impact factor: 5.614

Review 5.  Therapeutic perspectives of epigenetically active nutrients.

Authors:  M Remely; L Lovrecic; A L de la Garza; L Migliore; B Peterlin; F I Milagro; A J Martinez; A G Haslberger
Journal:  Br J Pharmacol       Date:  2014-12-15       Impact factor: 8.739

6.  Soy provides modest benefits on endothelial function without affecting inflammatory biomarkers in adults at cardiometabolic risk.

Authors:  Elizabeth J Reverri; Colette D LaSalle; Adrian A Franke; Francene M Steinberg
Journal:  Mol Nutr Food Res       Date:  2014-12-05       Impact factor: 5.914

7.  Association of equol producing status with aortic calcification in middle-aged Japanese men: The ERA JUMP study.

Authors:  Xiao Zhang; Akira Fujiyoshi; Vasudha Ahuja; Abhishek Vishnu; Emma Barinas-Mitchell; Aya Kadota; Katsuyuki Miura; Daniel Edmundowicz; Hirotsugu Ueshima; Akira Sekikawa
Journal:  Int J Cardiol       Date:  2022-02-02       Impact factor: 4.164

8.  Relationship of serum levels and dietary intake of isoflavone, and the novel bacterium Slackia sp. strain NATTS with the risk of prostate cancer: a case-control study among Japanese men.

Authors:  Yoshie Nagata; Yukiko Sugiyama; Fumimasa Fukuta; Akio Takayanagi; Naoya Masumori; Taiji Tsukamoto; Hiroshi Akasaka; Hirofumi Ohnishi; Shigeyuki Saitoh; Tetsuji Miura; Kaoru Moriyama; Hirokazu Tsuji; Hideyuki Akaza; Mitsuru Mori
Journal:  Int Urol Nephrol       Date:  2016-06-04       Impact factor: 2.370

Review 9.  The effect of soy isoflavones on arterial stiffness: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Brian Man; Chendi Cui; Xiao Zhang; Daisuke Sugiyama; Emma Barinas-Mitchell; Akira Sekikawa
Journal:  Eur J Nutr       Date:  2020-06-11       Impact factor: 5.614

Review 10.  Phytochemicals as Potential Epidrugs in Type 2 Diabetes Mellitus.

Authors:  Karina Ramírez-Alarcón; Montserrat Victoriano; Lorena Mardones; Marcelo Villagran; Ahmed Al-Harrasi; Ahmed Al-Rawahi; Natália Cruz-Martins; Javad Sharifi-Rad; Miquel Martorell
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-01       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.